VG Health

Lilly Asia Ventures Participates in Accro Bioscience's $50 Million Series C Financing

Investment firm Gambit Capital Management makes a new $26.54 million investment in Eli Lilly

Wells Fargo Raises UnitedHealth Group's Price Target to $397

Japan Approves Eli Lilly's Zepbound for Obstructive Sleep Apnea

Gilead Sciences Chief Communications Officer Johanna Mercier Sells Nearly 28k Shares for $3.55M

Bank of America Lowers Intuitive Surgical Target Price to $520, Maintains Buy Rating

Eli Lilly Scales Up AI-Driven Drug R&D and Production with Dell Solutions

Merck Plans to Issue $6 Billion in Bonds to Fund Terns Pharmaceutical Acquisition

Judge grants Luigi Mangione's request to suppress evidence in UnitedHealth CEO murder case

UnitedHealth Group will hold its Annual General Meeting on June 2, 2026

Harbour BioMed releases positive preclinical obesity data on its potential rival drug, LET003

Merck Announces Experimental Endometrial Cancer Drug Meets Primary Endpoint in Late-Stage Trial

Novo Nordisk plans to launch Wegovy oral weight-loss drug outside the US, intensifying competition with Eli Lilly

Eli Lilly announces its RET kinase inhibitor selpercatinib has entered a Phase III clinical trial for the first-line treatment of RET fusion-positive lung cancer

Berkshire Hathaway exited its entire position in UnitedHealth Group during the first quarter, causing the stock to slide 4% overnight.

Eli Lilly and other Fortune 500 pharmaceutical giants establish a presence in Beijing International Pharmaceutical Innovation Park

UnitedHealthcare's D.C. Community Plan Earns NCQA Distinction for Long-Term Services and Supports

Report claims Trump purchased Eli Lilly stock during period of favorable government policies

Investment firm GLOBALT increases its stake in Eli Lilly and Company

Multiple analyst firms update ratings and earnings forecasts for Eli Lilly

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Wellgistics Health

Huachen AI Parking Management Tech

GeoVax Labs

Sunshine Biopharma

AIM ImmunoTech

Virax Biolabs

NextNRG

GCT Semiconductor

Pinned News

置顶新闻

CICC Cuts ZAI LAB  TP to HKD20.2; 1Q Results In Line

ZLAB

LABU

CICC has reduced ZAI LAB's target price to HKD20.2 following a report indicating a 6% YoY revenue decline to USD99.6 million and a net loss of USD51 million in 1Q. The results met expectations. The broker highlighted ongoing Phase III trials and multiple candidates entering clinical stages. CICC adjusted its 2026 and 2027 earnings forecasts, predicting larger net losses, while maintaining an Outperform rating.

- CICC reported that ZAI LAB (09688.HK) had a revenue of USD 99.6 million in Q1, a 6% YoY decline, with a net loss of USD 51 million, aligning with expectations.  
- The company is advancing its pipeline, with Zoci in Phase III trials and ZL1503 and ZL6201 in earlier clinical stages, while recent earnings forecasts have been downgraded due to competitive pricing pressures.  
- CICC lowered the 2026 net loss projection for ZAI LAB from USD 226 million to USD 248 million and maintained an Outperform rating, reducing the target price by 8%.

AASTOCKS News

Zai Lab

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

iShares Biotechnology ETF

iShares US Pharma

Direxion S&P Biotech Bull 3X

ZAI LAB

CICC

BAYN

BAYRY

SBIO

Bayer AG announced that the U.S. FDA has granted Priority Review for Asundexian, an oral Factor Xla inhibitor aimed at preventing secondary strokes. This follows positive results from the Phase 3 OCEANIC-STROKE trial. The Priority Review designation highlights the urgency for new secondary stroke prevention methods. Stroke is a leading cause of death in the U.S., with 795,000 cases annually. Bayer's stock closed at $11.02, up 1.10%.

nasdaq

Bayer AG

Bayer

Health Care Select Sector SPDR

VanEck Biotech ETF

Ark Genomic Revolution ETF

iShares Global Healthcare

First Trust NYSE Arca Biotech Index Fd

ALPS Medical Breakthrough

Nasdaq

Bayer Aktiengesellschaft

Bayer Granted Priority Review For Asundexian In Secondary Stroke Prevention

UNHG

GSA Capital Partners LLP increased its stake in UnitedHealth Group (NYSE:UNH) by 203.2% in Q4, owning 6,673 shares valued at $2.2 million. Other institutional investors also raised their holdings. Analysts have upgraded their ratings, with Barclays setting a price target of $373.00. Despite Berkshire Hathaway's exit affecting sentiment, UnitedHealth's recent earnings showed positive results, maintaining a market cap of $354.57 billion.

Market Beat

Unitedhealth

iShares US Healthcare Providers

SPDR S&P Health

Leverage Shares 2X Long UNH Daily ETF

Barclays

Jefferies Financial

KeyCorp

Berkshire Hathaway

Berkshire Hathaway B

Thomson Reuters

KEYCORP DEP SHS REP 1/40TH NON CUM PER PFD SER G

KEYCORP DEP SHS REPSTG 1/40TH INT PERP NON CUM H

KEYCORP DEP SHS REP 1/40TH PERP PFD SER F USD25

KEYCORP DEP SHS REP 1/40TH NON CUM PFD SER E

UnitedHealth Group Incorporated $UNH Holdings Boosted by GSA Capital Partners LLP

Handelsbanken Fonder AB increased its stake in HCA Healthcare, Inc. by 7.9% in Q4, owning 213,272 shares valued at approximately $99.57 million. Other hedge funds also adjusted their positions. HCA's stock opened at $422.60, with a market cap of $93.75 billion. The company reported Q1 earnings of $7.15 per share, slightly below estimates, and announced a quarterly dividend of $0.78. Analysts have varied price targets, with UBS raising theirs to $635.00.

HCA Healthcare

UBS Group AG

Goldman Sachs

Toronto Dominion Bank

ROYAL BANK OF CANADA

GS Hldg R

Handelsbanken Fonder AB Boosts Position in HCA Healthcare, Inc. $HCA

HIMS

HIMZ

Hims & Hers Health has upsized its private offering of 0% convertible senior notes to $350 million, increased from $300 million. The offering, due June 1, 2032, includes a 13-day option for initial purchasers to buy an additional $52.5 million. Proceeds will fund capped call transactions, support the acquisition of Eucalyptus, and cover general corporate purposes. The offering is expected to close Thursday.

Fidelity

Hims & Hers Health

Defiance Daily Target 2X Long HIMS ETF

Hims & Hers Health Prices Upsized $350 Million Notes Offering

SBFMW

SBFM

Sunshine Biopharma Inc. has priced a $6 million public offering, consisting of 12 million common units at $0.50 each, sending shares up 79.51% to $0.51. The offering includes Series C warrants exercisable at $0.50 for five years. Proceeds will support corporate purposes and working capital. The company markets 60 generic drugs in Canada and plans to launch 12 more in 2026, while advancing proprietary programs targeting oncology and SARS-related coronaviruses.

SUNSHINE BIOPHARMA INC C/WTS (TO PUR COM)

Proshares Ultra Nasdaq Biotech

Sunshine Biopharma Prices $6M Offering; Closing May 19

NBIX

SLNO

Neurocrine Biosciences, Inc. presented new findings on INGREZZA's impact on mild tardive dyskinesia at the APA 2026 meeting, showing significant improvements in patient functional status. The company also completed its acquisition of Soleno Therapeutics for $2.9 billion, enhancing its rare disease portfolio. INGREZZA is FDA-approved for treating tardive dyskinesia and chorea associated with Huntington's disease. Neurocrine's stock closed at $157.21, down 0.76%, but rose 0.50% in after-hours trading.

Neurocrine Biosciences

Soleno Therapeutics

Neurocrine Unveils New INGREZZA Findings In Mild Tardive Dyskinesia At APA 2026; Closes Soleno Deal

BMRN

BioMarin’s BMN 401 raised plasma PPi over 52 weeks in children but showed no meaningful rickets or growth improvement. Shares fell about 3% to ~$50.10 after the announcement.12HC Wainwright & Co. reiterated a Neutral rating on BioMarin Pharmaceutical Inc. (BMRN) and lowered its price target for the stock from $55.00 to $50.00 per share.3

TradingView

BioMarin Pharma

Invesco Nasdaq Biotechnology ETF

Key facts: BMN 401 Raises Plasma PPi; No Rickets/Growth Benefit; PT $50

BRK.B

BRK.A

Berkshire Hathaway sold its entire stake in UnitedHealth in Q1 2026, leading to a decline in the insurer's stock. CEO Greg Abel's strategy reflects a shift towards quicker trades, contrasting with Warren Buffett's long-term approach. Despite the sell-off, UnitedHealth is exceeding earnings forecasts and focusing on AI investments and cost controls to enhance profitability.

- Berkshire Hathaway divested its entire UnitedHealth position in Q1 2026, leading to a decline in the insurer's stock.  
- CEO Greg Abel is adopting a strategy of quicker trades and capital redeployment, contrasting with Warren Buffett's long-term investment approach.  
- Despite the sell-off, UnitedHealth is exceeding earnings forecasts and focusing on AI investments and cost controls to enhance profitability.

Berkshire's UnitedHealth exit sends shares lower despite turnaround

LLYX

ELIL

Caliway Biopharmaceuticals presented preclinical data for its fat-reduction candidate CBL-514 combined with GLP-1 drugs at the European Congress on Obesity 2026. The studies showed enhanced weight-loss effects and potential metabolic benefits. The same data will be presented at the American Diabetes Association’s 2026 Scientific Sessions, with plans for human clinical studies this year, aiming for partnerships in obesity treatments.

PUBT

Eli Lilly

Defiance Daily Target 2X Long LLY ETF

Direxion Daily LLY Bull 2X Shares

Caliway touts preclinical CBL-514 combo data with semaglutide, tirzepatide at ECO 2026

RHHBY

Genentech presented new clinical data for giredestrant, an oral breast cancer drug, ahead of the ASCO 2026 meeting. The Phase III lidERA study will assess benefits across pre- and post-menopausal patients, supporting an FDA submission. Results from the persevERA study, despite missing its main goal, show numerical improvement in endocrine-sensitive disease. Additional analyses from the evERA trial will extend evidence for giredestrant in advanced breast cancer. Early safety and efficacy data for a HER2-targeted therapy will also be presented.

Roche

Genentech says Phase III lidERA data support giredestrant in early ER+ breast cancer

Novo Nordisk AS

Direxion Daily LLY Bear 1X Shares

Novo Nordisk's U.S. stock pre-market fell 11%, while Eli Lilly rose over 4% in pre-market trading. Novo Nordisk's CagriSema performed worse than Eli Lilly's Zepbound in trials

Wallstreetcn

VG Health(VHT.US)

CICC Cuts ZAI LAB TP to HKD20.2; 1Q Results In Line

Bayer Granted Priority Review For Asundexian In Secondary Stroke Prevention

UnitedHealth Group Incorporated $UNH Holdings Boosted by GSA Capital Partners LLP

Handelsbanken Fonder AB Boosts Position in HCA Healthcare, Inc. $HCA

Hims & Hers Health Prices Upsized $350 Million Notes Offering